

### **Evidence-based practice, systematic reviews and Cochrane**

#### **Martin Burton**

Director, Cochrane UK

Professor of Otolaryngology, University of Oxford

Co-ordinating Editor Cochrane ENT

Trusted evidence. Informed decisions.

Better health.








"On reflection it was not a good trial. I was testing the wrong hypothesis. The oedema was not wet beri-beri. Furthermore the numbers were too small, the time too short, and the outcome measure poor. Yet the treatment worked. I still do not know why.....

• • • •


The German doctor's remark when I asked for more help was "Artze sind überflüssing ("doctors are superfluous"). This was probably correct, but it was amazing what a little bit of science and a little bit of luck achieved"








Effectiveness and
Efficiency
Random Reflections on
Health Services
1972








"It is surely a great criticism of our profession that we have not organised a critical summary, by specialty or subspecialty, adapted periodically, of all relevant randomised controlled trials."



1988
Effective Care in Pregnancy and Childbirth





1988

Effective Care in Pregnancy and Childbirth

1992

First Cochrane Centre opened in Oxford



1988

Effective Care in Pregnancy and Childbirth

1992

First Cochrane Centre opened in Oxford 1993

The Cochrane Collaboration created







# Evidence based medicine:



### Evidence based medicine:

but

what does "evidence based" mean?



The conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients

Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. *BMJ* 1996;**312**:71–2.



The conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients

Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. *BMJ* 1996;**312**:71–2.



The conscientious, explicit and judicious use of current best evidence in helping individual patients make decisions about their care



The conscientious, explicit and judicious use of current best evidence in <a href="helping individual">helping individual</a> patients make decisions about their care



### Current best evidence is.....

- Up to date
- Relevant
- Comprehensive
- Unbiased
- Reliable
- Easy to access and use



# Where do we find "best evidence"?



# What sort of evidence are we looking for?

- Evidence from trials
- The types of trials most likely to give an unbiased result and be closest to "the truth"
- Randomized controlled trials (RCTs)



"Current medical reviews do not routinely use scientific methods to identify, assess, and synthesize information"





### Systematic reviews

A systematic review attempts to

- locate,
- appraise, and
- synthesize

evidence from scientific studies



# Systematic reviews

A systematic review attempts to

- locate,
- appraise, and
- synthesize

evidence from scientific studies

all the evidence that meets pre-specified criteria to answer a given research question.



# Systematic reviews

A systematic review attempts to

- locate,
- appraise, and
- synthesize

evidence from scientific studies

all the evidence that meets <u>pre-specified criteria</u> to answer a given research <u>question</u>.





#### **PICO**

- Which patients?
- Which intervention?
- Which comparison?
- Which outcome?

- P
- C



# Tonsillectomy?

In

children with recurrent tonsillitis and/or sore throats, is

tonsillectomy better than,

watchful waiting, in

reducing the number of sore throat episodes



# Tonsillectomy?

In

Participants children with recurrent tonsillitis

and/or sore throats, is

Intervention tonsillectomy better than,

**C**omparator watchful waiting, in

Outcome reducing the number of sore throat

episodes



#### PICO structure:

Should I take aspirin every day now I am 60?

Participant – 60 year old man, fairly fit and healthy

Intervention – daily aspirin 75mg

Comparison – no aspirin

Outcomes – death, myocardial infarction, stroke, side effects



#### PICO structure:

Should I take aspirin every day now I am 60?



stroke, side effects



**Participant** – what sort of people in the studies?

**Intervention** – what drug, treatment, dosage, intervention, time course

Comparison – placebo, 'standard care'



**Participant** – what sort of people in the studies?

**Intervention** – what drug, treatment, dosage, intervention, time course

Comparison – placebo, 'standard care'



**Participant** – what sort of people in the studies?

**Intervention** – what drug, treatment, dosage, intervention, time course

Comparison – placebo, 'standard care'



**Participant** – what sort of people in the studies?

**Intervention** – what drug, treatment, dosage, intervention, time course

Comparison – placebo, 'standard care'



# PICO structure: Getting this right

**Participant** – what sort of people in studies?

Intervention – what drug, treatment intervention, time course

Comparison – placebo, 'standard care'

Outcomes – what, when (time point), how measured, 'minimally clinically important effect'

Don't forget
'natural history' –
what if we do
nothing?



# PICO structure: Getting this right

**Participant** – what sort of people in the studies?

**Intervention** – what drug, treatment, dosage, intervention, time course

Comparison – placebo, 'standard care'

**Outcomes** – what, when (time point), how measured, 'minimally clinically important effect'



# PICO structure: Getting this right

Participant – what sort of people in the

studies?

Intervention – what drug, treatment intervention, time course

**Comparison** – placebo, 'standard ca for this individual

generally,

..for patients

Outcomes – what, when (time point), how measured, 'minimally clinically important & effect'



Why systematic reviews?



# Digression or clarification













## Odds versus Risk

Object	Sides	Risk or chance	Odds
Coin	2	1 in 2 = 0.5	1 to 1 = 1
Dice	6	1 in 6 = 0.16	1 to 5 = 0.2
Polygon	1000	1 in 1000 =0.001	1 to 999≈ 0.001




Review: Antibiotic prophylaxis in clean and clean-contaminated ear surgery Comparison: 1 Antibiotics in clean and clean-contaminated ear surgery Outcome: 1 Effect of antibiotics on postoperative infection within three weeks after surgery

Study or subgroup	Treatment n/N	Control n/N	Odds Ratio M - H, Fixed, 95% CI	Weight	Odds Ratio M-H,Fixed,95% CI	
Bagger-Sjoback 1987	9/47	10/44		22.5 %	0.81 [0.29, 2.22]	
Donaldson 1966	1/48	3/48 +		7.9 %	0.32 [ 0.03, 3.18 ]	
Eschelman 1971	9/75	4/33		13.2 %	0.99 [ 0.28, 3.47 ]	
Govaerts 1998	12/380	17/370		44.9 %	0.68 [ 0.32, 1.44 ]	
Hester 1998	1/71	4/75 ←	-	10.3%	0.25 [ 0.03, 2.33 ]	
Pirodda 1994	2/50	0/50		1.3 %	5.21 [ 0.24, 111.24 ]	
<b>Total (95% CI)</b> Total events: 34 (Treatment) Heterogeneity: Chi <sup>2</sup> = 3.25, Test for overall effect: Z = 1	$df = 5 (P = 0.66); I^2 :$	<b>620</b> =0.0%	•	100.0 %	0.73 [ 0.45, 1.20 ]	
	I	0.1 avours treatment	0.2 0.5 1.0 2.0 5 Favours c	i.0 10.0 ontrol		




Review: Antibiotic prophylaxis in clean and clean-contaminated ear surgery Comparison: 1 Antibiotics in clean and clean-contaminated ear surgery Outcome: 1 Effect of antibiotics on postoperative infection within three weeks after surgery

There is a label to tell you what the comparison is and what the outcome of interest is











The label above the graph tells you what statistic has been used





- Each study is given a blob, placed where the data measure the effect.
- The size of the blob is proportional to the % weight
- The horizontal line a 95% confidence interval



At the bottom there's a horizontal line. This is the scale measuring the treatment effect.

Here the outcome is the effect of antibiotics on post-op infection (lower is better).





The vertical line in the middle is where the treatment and control have the same effect – there is no difference between the two




**Total (95% CI)** 671 620 Total events: 34 (Treatment), 38 (Control)

Heterogeneity: Chi<sup>2</sup> = 3.25, df = 5 (P = 0.66); I<sup>2</sup> = 0.0%

Test for overall effect: Z = 1.24 (P = 0.22)



The pooled analysis is given a diamond shape where the widest bit in the middle is located at the calculated best guess (point estimate), and the horizontal width is the confidence interval



## Note on interpretation

If the confidence interval crosses the line of no effect, this is equivalent to saying that we have found no statistically significant difference in the effects of the two interventions




Review: Antibiotic prophylaxis in clean and clean-contaminated ear surgery Comparison: 1 Antibiotics in clean and clean-contaminated ear surgery Outcome: 1 Effect of antibiotics on postoperative infection within three weeks after surgery

Study or subgroup	Treatment n/N	Control n/N	Odds Ratio M - H, Fixed, 95% CI	Weight	Odds Ratio M-H,Fixed,95% CI	
Bagger-Sjoback 1987	9/47	10/44		22.5 %	0.81 [0.29, 2.22]	
Donaldson 1966	1/48	3/48 +		7.9 %	0.32 [ 0.03, 3.18 ]	
Eschelman 1971	9/75	4/33		13.2 %	0.99 [ 0.28, 3.47 ]	
Govaerts 1998	12/380	17/370		44.9 %	0.68 [ 0.32, 1.44 ]	
Hester 1998	1/71	4/75 ←	-	10.3%	0.25 [ 0.03, 2.33 ]	
Pirodda 1994	2/50	0/50		1.3 %	5.21 [ 0.24, 111.24 ]	
<b>Total (95% CI)</b> Total events: 34 (Treatment) Heterogeneity: Chi <sup>2</sup> = 3.25, Test for overall effect: Z = 1	$df = 5 (P = 0.66); I^2 :$	<b>620</b> =0.0%	•	100.0 %	0.73 [ 0.45, 1.20 ]	
	I	0.1 avours treatment	0.2 0.5 1.0 2.0 5 Favours c	i.0 10.0 ontrol		

## Individual Analysis and Conventional Meta-Analysis (odds ratio)

Cumulative Mantel-Haenszel Method (odds ratio)




IV streptokinase for acute myocardial infarction

Lau J et al. Cumulative meta-analysis of therapeutic trials for myocardial infarction. NEJM 1992 327:248-54.


## Individual Analysis and Conventional Meta-Analysis (odds ratio)


Cumulative Mantel-Haenszel Method (odds ratio)




## Individual Analysis and Conventional Meta-Analysis (odds ratio)


## Cumulative Mantel-Haenszel Method (odds ratio)






Lau J et al. Cumulative meta-analysis of therapeutic trials for myocardial infarction. NEJM 1992 327:248-54.





Antman E et al. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. JAMA 1992 268(2):240-8






Why systematic reviews?



## Current best evidence:

Up-to-date systematic reviews of RCTs






## **About Cochrane**






# Cochrane Review Groups by health topic. The circle size is proportional to the number of reviews published by the group





## **Cochrane Library**





Trusted evidence. Informed decisions. Better health. English

Cochrane.org ☑

Sign In

Title Abstract Keyword ▼

Browse

Advanced search


Cochrane Reviews -

Trials -

Clinical Answers -

About ▼

Help ▼



Can a Mediterranean-style diet prevent cardiovascular disease? Read the Review





**Highlighted Reviews** 

Editorials

Special Collections

#### Support during pregnancy for women at increased risk of low birthweight babies

Christine E East, Mary A Biro, Suzanne Fredericks, Rosalind Lau 1 April 2019

#### Lifestyle changes in women with polycystic ovary syndrome

Siew S Lim, Samantha K Hutchison, Emer Van Ryswyk, Robert J Norman, Helena J Teede, Lisa J Moran 28 March 2019

#### Benzodiazepines versus placebo for panic disorder in adults

Johanna Breilmann, Francesca Girlanda, Giuseppe Guaiana, Corrado Barbui, Andrea Cipriani, Mariasole Castellazzi, Irene Bighelli, Simon JC Davies, Toshi A Furukawa, Markus Koesters



Cochrane Interactive Learning Learn how to conduct Cochrane Reviews with Cochrane Interactive Learning



## **Our ENT content**

133 Reviews

55 Protocols

Suites of reviews on common topics:

- Chronic rhinosinusitis
- CSOM
- Tinnitus

## **Evidently Cochrane**

Sharing health evidence you can trust






EVIDENCE FOR EVERYDAY NURSING



Oral cryotherapy: preventing mouth soreness and ulcers in people having cancer treatments




## **Evidently Cochrane**

Sharing health evidence you can trust







#### LATEST ARTICLES



Survey: Evidently Cochrane - are we reaching you?



Cryotherapy: it's cool, but is it evidence-based?

Rugby players and celebrities swear by it



My treatment, my choice: what do I need to know?

#### **NEWSLETTER**

#### **Email address:**

Your email address

Sign up

#### **TWITTER**

RT @mgtmurphy123: @flowepower66 @campaignforleo @midwivesIrl @UKCochraneCentr @WeMidwives @SagefemmeSB @JennytheM @HSElive

## **Evidently Cochrane**

Sharing health evidence you can trust





#### CATEGORY ARCHIVES: CANCER



#### Unprovoked venous thromboembolism: should we be looking for cancer?

Retired GP Lynda Ware looks at new evidence on whether unprovoked venous thromboembolism warrants cancer screening

@ MARCH 24, 2015



Can sentinel node assessment help women with vulval cancer avoid unnecessary surgery?



#### Treating children with cancer: looking to the future

As more children are surviving cancer, we need research into kinder treatments

O JANUARY 23, 2015



Breast cancer: your treatment, your choice

#### NEWSLETTER

#### Email address:

Your email address

Sign up

#### **TWITTER**

Preventing mouth ulcers in people having chemo: Evidently #Cochrane blog https://t.co/Hpg8LCKY54 #WorldCancerDay @amandaneylon @Oh\_henry about 7 minutes ago from Hootsuite

Reply Retweet Favorite

It's #WorldCancerDay. Catch up with our Evidently #Cochrane blogs on #cancer evidence & experience https://t.co /DPwscA1sKg @amandaneylon about 12 minutes ago from Hootsuite

Reply Retweet Favorite

Follow Bukcochranecentr 13.6K followers

#### RECENT COMMENTS

Wendy Thompson on New Lancet Breastfeeding Series is a call to action

Tina Foster on Learning to love our hearing aids. The good, the bad, the ugly and the evidence

Paul on New Lancet Breastfeeding Series



# Don't go large! Portion size infographic

### **NEW COCHRANE EVIDENCE SHOWS** WE ALL CONSUME TOO MUCH...










...food & non-alcoholic drink when offered bigger portions, bigger packaging or bigger tableware rather than smaller sizes, regardless of other factors such as gender, BMI or self-control.



Cochrane









## Blogshots

### **Evidently Cochrane**

Sharing health evidence you can trust







No evidence that whole-body cryotherapy is a safe or effective treatment for muscle soreness after exercise



New Cochrane review. 4 randomized controlled trials, 64 adults. Whole-body cryotherapy compared with rest or no treatment and with far-infrared therapy



Very low quality evidence (GRADE)



Find out more in this Evidently Cochrane blog: http://bit.ly/1RfPJt0

evidentlycochrane.org | @ukcochranecentr | #cochraneevidence #blogshot #cryotherapy #musculoskeletal #exercise






## Engagement programme

- Evidently Cochrane
- Evidence for Everyday Nursing
- Evidence for Everyday Midwifery
- Students 4 Best Evidence




### **Evidence for Everyday Nursing**






### **Evidence for Everyday Midwifery**





### Students 4 Best Evidence





### What is Students 4 Best Evidence?

S4BE is a growing network of students from around the world interested in learning more about evidence-based health care.

- Reviewing evidence-based resources
- Writing tutorials explaining evidence-based concepts
- Blogging about the latest evidence

... S4BE.org



# **About Cochrane**





# EBM in day-to-day practice

Explaining to patients & the public



# **Sharing uncertainty**



# Well informed uncertainties about the effects of treatments

How should clinicians and patients respond?

The patient's about the effects of treatments are inevitable. Whatever the basis for judgments about the likely effects of treatments in individual patients, there is no escape from the reality that every such judgment initiates a clinical trial in which there can be no certainty that an individual patient will benefit. Sometimes the judgment will draw on the patient's past experience of the treatment, more usually on the clinician's experience of treating other patients. Increasingly, clinicians and patients are

response to uncertainty can be substantial: gradual and important improvements in the prognosis of children with leukaemia, for example, seem likely to reflect an expectation among paediatric oncologists that decisions about treatment should be taken within the context of controlled trials, so that uncertainties can be addressed and reduced.

Strategies for dealing with uncertainty need to be considered and debated more explicitly. For example, what does the "quality in health care" movement



"A pre-requisite for constructive debate about uncertainties about the effects of treatments is a greater willingness...to admit and discuss them, combined with humility to acknowledge that good intentions alone have not protected patients from the unintended harmful effects of treatments"



# Will the patients & the public understand?



#### UNDERSTANDING HEALTH STATISTICS

# KNOW YOUR CHANCES

HOW TO SEE
THROUGH THE HYPE IN
MEDICAL NEWS, ADS,
AND PUBLIC SERVICE
ANNOUNCEMENTS



Steven Woloshin, MD, MS, Lisa M. Schwartz, MD, MS, and H. Gilbert Welch, MD, MPH



A person taking Drug A has a 1% chance of having an allergic reaction. If 1,000 people take Drug A, how many would you expect to have an allergic reaction?



A person taking Drug A has a 1% chance of having an allergic reaction. If 1,000 people take Drug A, how many would you expect to have an allergic reaction?

A person taking Drug B has a 1 in 1,000 chance of having an allergic reaction. What percentage of people taking Drug B will have an allergic reaction?



A person taking Drug A has a 1% chance of having an allergic reaction. If 1,000 people take Drug A, how many would you expect to have an allergic reaction?

A person taking Drug B has a 1in 1,000 chance of having an allergic reaction. What percentage of people taking Drug B will have an allergic reaction?

Imagine that I flip a coin 1,000 times. What is your best guess about how many times the coin would come up heads in 1,000 flips?



	US Adults ages 35-70 n=450	Postgrad. degree n=62	US Adults ages 26-69 n=1009	German adults ages 25-69 n=1001	
	% Correct answers				
Convert 1% to 10 in 1,000	70				
Convert 1 in 1,000 to 0.1%	25				
Heads in 1,000 coin flips	76				



	US Adults ages 35-70 n=450	Postgrad. degree n=62	US Adults ages 26-69 n=1009	German adults ages 25-69 n=1001
		% Correct answers		
Convert 1% to 10 in 1,000	70	82		
Convert 1 in 1,000 to 0.1%	25	27		
Heads in 1,000 coin flips	76	86		



	US Adults ages 35-70 n=450	Postgrad. degree n=62	US Adults ages 26-69 n=1009	German adults ages 25-69 n=1001
		% Correct answers		
Convert 1% to 10 in 1,000	70	82	58	68
Convert 1 in 1,000 to 0.1%	25	27	24	46
Heads in 1,000 coin flips	76	86	73	73



# Physicians

% Correct answers

Convert 1% to 10 in 1,000	All three correct	
Convert 1 in 1,000 to 0.1%		
Heads in 1,000 coin flips		



# Physicians

% Correct answers All three Convert 1% to 10 correct in 1,000 Convert 1 in 1,000 to 0.1% Heads in 1,000 coin flips



# Physicians

% Correct answers				
Convert 1% to 10 in 1,000		All three correct		
Convert 1 in 1,000 to 0.1%		<b>72</b> %		
Heads in 1,000 coin flips				




Patients <u>and</u> physicians need to get better at explaining and understanding uncertainty



Trusted evidence.
Informed decisions.

Better health.





## Lessons to be learnt

- "Evidence-based" is easy to say less easy to do
- A conscientious, explicit & judicious process focused on using the current best evidence
- A culture of seeking to generate better evidence



## Lessons to be learnt 2

- What sort of study is "best" or "good enough?"
- Does it work?



## Lessons to be learnt 2


- What sort of study is "best" or "good enough?"
- Does it work?
- Does it do more good than harm?



martin.burton@cochrane.nhs.uk



Trusted evidence.
Informed decisions.
Better health.





# Chronic Rhinosinusitis: prioritising a suite of systematic reviews

Trusted evidence. Informed decisions.

Better health.



## Introduction

- How we used to prioritise
- The need to be more focused
- Funder's request
- Cochrane ENT's response
  - Which are the most important reviews?
    - New reviews
    - Up-dated reviews
  - How big is the task?
- The offer: a scoping documents produced in 2 months
  - A prioritised list of reviews
  - A "cut-off"



### Clinical need for the review of evidence

Epidemiology and burden of disease [UK focused; for funders]

Description of interventions



### Pharmacological interventions commonly used include:

- Intranasal corticosteroids (INCS)
- Systemic steroids
- Antibiotics

### Types of surgery include:

- Endoscopic sinus surgery; including balloon sinuplasty and surgery of differing extent
- Open approaches to the sinuses (rarely used)

### Other interventions used (or misused):

- Nasal irrigations, including
  - high- and low-volume irrigations,
  - differing solutions (such as saline or buffered saline), differing strength of solutions and
  - irrigations with additives such as surfactants or xylitol
- Antifungals, either topical or systemic
- Local decongestants



### Clinical need for the review of evidence

- Epidemiology and burden of disease [UK focused; for funders]
- Clinical practice
  - Description of interventions
  - How they might work
- Clinical issues and variation in practice
  - European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) 2012
  - Variation in antibiotic usage
  - Variation in surgery: when to operate and what to do?
- Where is the evidence now?
- Which areas require up-to-date evidence synthesis?



### **Current evidence**

- New searches
- Clinical guidelines
- Health technology assessment reports
- 10 existing Cochrane reviews:
  - 5 pharmacological: 2 CRS with polyps, 2 without & 1 anti-fungals
  - 2 surgery
  - 2 different surgical techniques
  - 1 saline



### **Current evidence**

Largest body of evidence: topical steroids

Over 260 new abstracts to screen for new RCTs in this area

Oral steroids: 433 new abstracts

**Antibiotics**: 546 new abstracts

**Saline irrigation**: 540 new abstracts

leukotriene antagonists: 381

anti-IL-5: 624

anti-lgE: 471

local decongestants

antihistamines

capsaicin: 59



**Current evidence** 

Surgery

HTA review 2003 - need for high quality studies on FESS

2014 Cochrane reviews – urgent need for further studies



Which areas most require an up-to-date evidence synthesis?

Intranasal corticosteroids: commonly used

Oral steroids: widely used

Saline irrigation: widely adopted, "does no harm"

Antibiotics: often prescribed

Anti-fungals: regularly prescribed

Decongestants: often bought "over the counter"



**Proposed scope of the reviews** 

Setting

**Population** 

**Interventions** 

Comparators

**Outcomes** 

"PICO again"



**Proposed scope of the reviews** 

Population

Patients with CRS with or without nasal polyps

#### **Excluding:**

- Allergic fungal rhinosinusitis/eosinophilic fungal/mucinous rhinosinusitis (except for the review(s) on antifungals)
- Aspirin-exacerbated respiratory disease (aka Samter's triad)
- Cystic fibrosis
- Peri-operative patients



#### **Proposed scope of the reviews**

Interventions – a prioritised list

**Topical steroids** 

Oral steroids

Antibiotics (both topical and oral)

Saline irrigation

**Antifungals** 

Local decongestants

Nasal (saline) irrigation

Anti-IL-5

Anti-leukotrienes

Anti-IgE

Capsaicin

**Antihistamines** 



#### **Proposed scope of the reviews**

#### **Outcomes 1**

- **Disease severity**, as measured by patient-reported symptom score (such as the Chronic Sinusitis Survey (CSS), Lund-Mackay scale, visual analogue scales).
- Health-related quality of life, using disease-specific health-related quality of life scores, such as the Sino-Nasal Outcome Test-22 (SNOT-22), Rhinosinusitis Outcome Measures-31 (RSOM-31) and SNOT-20.
- Health-related quality of life, using generic quality of life scores, such as the SF-36, EQ-5D and other well-validated instruments.



#### **Proposed scope of the reviews**

#### Outcomes 2

- Recurrence of symptoms
- Endoscopic appearances
- **Complications** or **adverse effects** from treatment; for example: epistaxis, infection, orbital complications, intracranial complications
- Objective physiological measures: nasal peak flow, nasal volume, nasal cross-sectional area, nasal nitric oxide (nNO), ciliary function (including saccharine clearance time)
- Olfactory tests



**Proposed scope of the reviews** 

**Review Questions** 



(Tentative) Review short name		Pair	Population <sup>3</sup>	Intervention <sup>2</sup>	Comparison
1.	INCS	1.	CRS	INCS	Placebo/no intervention
2.	Relative effectiveness	2.	CRS	INCS type A	INCS type B
	of INCS	3.	CRS	INCS delivery method A	INCS delivery method B
		4.	CRS	High-dose INCS	Low-dose INCS
3.	Oral steroids (short	5.	CRS	Oral steroids	Placebo/no intervention
	course)	6.	CRS	Oral steroids	Other pharmacological treatments
4.	Oral steroids (short course) as an add-on therapy	7.	CRS, currently using INCS	Oral steroids + INCS	INCS + placebo/no intervention
		8.	CRS currently using INCS plus antibiotics	Oral steroid + INCS + antibiotics	INCS + antibiotics + placebo/no intervention
5.	Antibiotics (systemic	9.	CRS	Antibiotics	Placebo
	and topical)	10.	CRS	Antibiotics A	Antibiotics B
		11.	CRS, currently using INCS	Antibiotics + INCS	Placebo + INCS
		12.	CRS, currently using INCS	Antibiotics + oral steroids + INCS	Oral steroids + INCS



<ol><li>Saline irrigation</li></ol>	13.	CRS	Saline irrigation	Placebo
	14.	CRS	Saline irrigation A	Other types or volume of nasal irrigation
	15.	CRS, on standard therapy	Saline irrigation + standard therapy <sup>5</sup>	Placebo + standard therapy
<ol><li>Antifungals (systemic and topical)</li></ol>	16.	CRS <sup>e</sup>	Antifungals	Placebo
	17.	CRS	Antifungal A	Antifungal B
8. Local decongestants	18.	CRS	Local decongestants	Placebo
	19.	CRS	Local decongestants + standard therapy	Placebo/no intervention + standard therapy
9. Anti-IL-5	20.	CRS	IL-5	Placebo
	21.	CRS	IL-5 + standard therapy	Standard therapy
<ol><li>Leukotriene</li></ol>	22.	CRS	Leukotriene antagonists	Placebo
antagonists	23.	CRS	Leukotriene antagonists + standard therapy	Standard therapy
<ol><li>Anti-IgE monoclonal</li></ol>	24.	CRS	Anti Ig E	Placebo
antibodies	25.	CRS	Anti IgE + standard therapy	Standard therapy
<ol><li>Capsaicin</li></ol>	26.	CRS	Capsaicin	Placebo
	27.	CRS	Capsaicin + standard therapy	Standard therapy
<ol><li>Antihistamines</li></ol>	28.	CRS	Antihistamines	Placebo
	29.	CRS	Antihistamines	Standard therapy



#### **Review methods**

#### Searches

Study design: key issues:

- Randomisation by side of nose?
- Length of follow-up (specified 3 months minimum)

#### Analysis and pooling

- Subgroups of with/without nasal polyps
- Pre-determined time-points for analyses



### What we learnt 1

#### **Understanding the clinical context**

Helpful to have clear definitions of different phenotypes (EPOS 2012)

# Collaborating with clinicians and research groups to identify key issues, target audiences and outcomes

Engagement of primary and secondary care physicians.....and patients

- Primary care physicians treat majority of patients with only history and limited examination information
- 2. Prioritisation of medical over surgical interventions
- 3. Used results of two research prioritisation exercises to inform choice of outcomes; GENERATE and OMIPP



### What we learnt 2

#### Mapping the existing evidence

Original separation of two major phenotypes

Identified need to use core set of outcomes across all reviews

#### **Searching the current research evidence**

Identifying the need for systematic reviews

Helping assess the scale of the task

Review of literature around outcomes

#### Identifying the priority areas for reviews

Prioritisation by clinical importance with patient input



### What we learnt 3

#### **Defining the research questions for individual reviews**

Deciding of specific reviews required specific outcomes

3 main outcomes (one being most common or important adverse effect)

Identifying time and budget restraints for completing the work

#### Added value of the scoping process

- Prioritized list of reviews in an important clinical area
- "Horizon scanning" element useful in identifying "emerging technologies"
- Identification and resolution of some methodological issues at early stage



### The resulting reviews

- Intranasal steroids versus placebo
- Different types of intranasal steroids
- Short course of oral steroids
- Short course of oral steroids as an adjunct to other therapy
- Antibiotics: systemic and topical
- Saline irrigation